Seda Kahraman

Ankara Yıldırım Beyazıt University — Turkey

Medicine · Health Sciences

8h-index254citations60works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Advanced Breast Cancer Therapies(14), Lung Cancer Treatments and Mutations(11), Breast Cancer Treatment Studies(9), HER2/EGFR in Cancer Research(7), Cancer Immunotherapy and Biomarkers(5)

Publications59 total

Evaluation of the efficacy and tolerability of bevacizumab-based treatments in recurrent primary brain tumors: a multicenter real-world Turkish Oncology Group (TOG) study
BMC Cancer·2026Open Access
Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group
Clinical Lung Cancer·2025· 2 cited
HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy
Turkish Journal of Clinics and Laboratory·2025· 1 citedOpen Access
Advanced cervical cancer: how to interpret the new standard of care
Journal of Health Sciences and Medicine·2025Open Access
Real-life data on adjuvant trastuzumab emtansine treatment in early-stage HER2-positive breast cancer: a Turkish Oncology Group study
Anti-Cancer Drugs·2025· 1 cited
Association of lysyl oxidase expression with clinicopathological features in colorectal adenocarcinomas
International Journal of Colorectal Disease·2025Open Access
Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study
Clinical Breast Cancer·2025· 2 cited
Comparison of Standard Neoadjuvant Therapy and Total Neoadjuvant Therapy in Terms of Effectiveness in Patients Diagnosed with Locally Advanced Rectal Cancer
Medicina·2025Open Access
Hormon reseptörü pozitif, HER2 negatif metastatik meme kanseri tanısıyla ribosiklib veya palbosiklib ile letrozol kombinasyon tedavisi verilen hastalarda HER2-düşük ekspresyonunun önemi
DergiPark (Istanbul University)·2025Open Access
Understanding of Clinical Trials Among Patients With Cancer and Their Relatives
JAMA Network Open·2025· 3 citedOpen Access
Endocrine Adverse Events in Patients Treated with Immune Checkpoint Inhibitors: A Comprehensive Analysis
Medicina·2025· 7 citedOpen Access
Impact of HIF-1α, LOX and ITGA5 Synergistic Interaction in the Tumor Microenvironment on Colorectal Cancer Prognosis
Diagnostics·2025· 1 citedOpen Access
The Comparative Frequency of Breast Cancer-Related Lymphedema Determined by Perometer and Circumferential Measurements: Relationship with Functional Status and Quality of Life
Lymphatic Research and Biology·2025· 2 cited
Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study
BMC Cancer·2024· 4 citedOpen Access
Endocrine Adverse Events in Patients Treated with Immune Checkpoint Inhibitors: A Comprehensive Analysis
Preprints.org·2024Open Access
A Rare Case of Metachronous Tumor: Recurrent Primary Lung Cancer
Cureus·2024Open Access
Are the clinical trials in lung cancer an advantage for patients in developing countries?
Journal of Clinical Oncology·2024· 2 cited
Characteristic features and prognostic factors in gastric cancer patients with bone metastases: multicenter experience
Journal of Chemotherapy·2024· 2 cited
223P Real-world treatment efficacy of ribociclib or palbociclib plus fulvestrant in hormone receptor-positive/HER2-negative metastatic breast cancer: Turkish Oncology Group (TOG) study
ESMO Open·2024· 2 citedOpen Access
Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases
Scientific Reports·2024· 12 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Mehmet Alı Nahıt Şendur(29), Ertuğrul Bayram(15), Mutlu Hızal(14), Teoman Şakalar(13), İlhan Hacıbekiroğlu(13), Merve Keskinkılıç(12), Cihan Erol(12), Musa Barış Aykan(12), Nail Paksoy(11), Burçin Çakan Demirel(11), Burcu Gülbağcı(11), Naziyet Köse Baytemür(10), Elif Şahin(10), Arzu Yaren(10), Nuri Karadurmuş(10), Burak Bi̇lgi̇n(10), Bülent Yalçın(10), Mustafa Seyyar(9), Serkan Menekşe(9), Semra Paydaş(9)